Table 2.
Univariate and multivariable proportional hazards model for disease-free survival for circulating tumor cell count before chemotherapy (n = 2026)*
| Variable | Univariate analysis | Multivariable analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| CTCs in blood, negative vs positive | 2.257 (1.595 to 3.195) | <.0001 | 2.107 (1.487 to 2.986) | <.0001 |
| Hormone receptor status, positive vs negative | 2.187 (1.559 to 3.066) | <.0001 | 1.972 (1.363 to 2.854) | .0003 |
| Lymph node involvement, N0 vs N1–3 | 1.780 (1.187 to 2.670) | .005 | 2.942 (1.922 to 4.505) | <.0001 |
| Grading, G1 vs G2–3 | 3.109 (2.124 to 4.551) | <.0001 | 3.254 (2.146 to 4.935) | <.0001 |
| Tumor size, T1 vs T2–4 | 2.205 (1.496 to 3.251) | <.0001 | 2.082 (1.405 to 3.083) | .0003 |
| Menopausal status, pre vs post | 1.221 (0.864 to 1.725) | .26 | 1.018 (0.717 to 1.445) | .92 |
| Histology, lobular/mixed vs ductal | 1.308 (0.822 to 2.083) | .26 | 0.931 (0.575 to 1.508) | .77 |
* Cox proportional hazards models. All statistical tests were two-sided. CI = confidence interval; CTC = circulating tumor cell; HR = hazard ratio.